Corient Private Wealth LP Takes Position in DaVita Inc. $DVA

Corient Private Wealth LP acquired a new position in DaVita Inc. (NYSE:DVA) in the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 31,117 shares of the company’s stock, valued at approximately $6,917,000.

A number of other institutional investors have also recently made changes to their positions in DVA. Bank of America Corp DE bought a new stake in shares of DaVita in the second quarter worth approximately $145,057,000. Berkshire Hathaway Inc bought a new position in DaVita during the second quarter valued at approximately $6,425,269,000. Caisse de depot et placement du Quebec purchased a new stake in DaVita in the second quarter worth approximately $8,721,000. Invst LLC purchased a new stake in DaVita in the second quarter worth approximately $1,238,000. Finally, Jupiter Topco LLC bought a new stake in DaVita in the 2nd quarter worth approximately $9,030,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DVA. UBS Group increased their price target on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Oppenheimer set a $220.00 price objective on DaVita in a report on Friday, August 7th. Barclays upped their price objective on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Raymond James Financial set a $220.00 target price on DaVita in a research report on Friday, August 7th. Finally, TD Cowen raised shares of DaVita from a “hold” rating to a “buy” rating and upped their price target for the company from $201.00 to $220.00 in a research report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $221.75.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares in the company, valued at $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.90% of the stock is currently owned by insiders.

DaVita Price Performance

Shares of DaVita stock opened at $180.72 on Monday. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $247.49. The company’s fifty day simple moving average is $211.96 and its 200-day simple moving average is $183.37. The stock has a market capitalization of $11.53 billion, a PE ratio of 14.79, a P/E/G ratio of 0.47 and a beta of 0.88.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same period in the prior year, the business posted $2.95 EPS. DaVita’s revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, research analysts anticipate that DaVita Inc. will post 14.57 EPS for the current year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.